ASCO '23 Entrees
OncoPharm
00:00
The Effects of a CDK-46 Inhibitor on Progression-Free Survival
There was no significant difference in progression-free survival. Median PFS2 of 31 months versus 28 months, so three months, maybe saving without progression. However, their hazard ratio for overall survival was 0.98,. With a 95% confidence, it'll be 0.8 to 1.2. No difference in long-term survival for this study.
Transcript
Play full episode
